- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04952480
Radioterapia Adaptativa de Dose Escalonada de Doença Torácica para Câncer de Pulmão de Pequenas Células (DARTS)
Radioterapia Adaptativa de Dose Escalonada da Doença Torácica para Câncer de Pulmão de Pequenas Células (DARTS): Um Estudo Prospectivo de Fase II Avaliando o Controle Local da Radioterapia Adaptativa de Dose Escalada
The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This will be an open-label, single-arm, phase II study comparing dose escalated adaptive thoracic radiotherapy to historical control of standard of care single planned radiotherapy field for entire treatment course in patients with newly diagnosed limited stage small cell lung cancer eligible for concurrent chemoradiation with platinum doublet based chemotherapy, or extensive stage small cell lung cancer patients with radiation-targetable intra-thoracic disease and none or limited extra-thoracic disease that are eligible for up-front platinum doublet chemotherapy and are fit to receive concurrent radiotherapy.
The adaptive dose-escalated radiotherapy treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk. Up to 70 Gy in 35 fractions can be delivered to the disease without overdosing organs-at-risk, and treatment will last 5 - 7 weeks. Scheduled CT simulations for the replans will be at fraction 5 and fraction 10 to account for the expected rapidly shrinking tumour volumes. Participants will be followed for 24 months to investigate local failure rate, medium progression-free survival, overall survival, acute radiation toxicity, and late radiation toxicity. Follow-up after the study will be as per standard-of-care for secondary endpoints.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Yee Don, MD
- Número de telefone: 780-432-8783
- E-mail: don.yee@ahs.ca
Locais de estudo
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Recrutamento
- Cross Cancer Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Minimum 18 years of age
- Biopsy proven, newly diagnosed, untreated SCLC
- Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan and/or or PET-CT scan, CT head or MRI brain, or chest X-ray
- Eligible for platinum doublet chemotherapy
- Eligible for thoracic radiotherapy, which can also include ipsilateral supraclavicular lymph node disease
- Capable of providing written, informed consent prior to participation in the study. Patient's legally authorized representative (LAR) may sign on behalf of the patient.
- Able and willing to comply with protocol rules and follow-up regimen
- Performance status of ECOG 0-2
- Pulmonary function tests showing FEV-1 >1.0L and DLCO > 50% predicted
- Radiation-targetable intrathoracic disease
Exclusion Criteria:
- No intrathoracic disease seen to target with radiation
- Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes
- Mixed histology disease
- Active serious infection requiring therapy
- Brain metastasis that has not been symptomatically stable on dexamethasone
- 4 or more sites of extrathoracic disease, even if 2 or more of these are present in the same organ system
- Previous CNS or thoracic radiotherapy
- Previous chemotherapy
- Ineligibility for platinum doublet chemotherapy
- Life expectancy of less than 3 months
- Prior thoracic surgery
- History of another primary malignancy other than cutaneous basal cell carcinoma unless disease-free for at least 5 years
- Pregnant or breast-feeding
- In LS-SCLC, patients that are not eligible for concurrent chemoradiotherapy
- In ES-SCLC, patients that are not eligible for concurrent chemoradiotherapy under the experimental arm
- CT contrast allergy or kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging)
- Lack of intrathoracic disease or intrathoracic disease spread not feasible to treat with adaptive radiotherapy
- Participant in development and conduct of the research study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Dose-escalated adaptive chemoradiotherapy
Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk: Phase 1 dose prescription = 14 Gy in 7 fractions; Phase 2 dose prescription = 10 Gy in 5 fractions starting the day after the final (7th) fraction is delivered; Phase 3 dose prescription = either a) 70 Gy in 35 fractions, or if this cannot be safely reached without exceeding the dose limit of an organ-at-risk, b) the maximum safe prescribe-able dose tolerance specified in the protocol. Either 3D conformal radiotherapy or IMRT planning and delivery techniques will be employed, including contouring relevant thoracic organs-at-risk. All CT simulation scans will be without contrast. |
Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk. Concurrent standard of care platinum doublet based therapy |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Local failure rate
Prazo: The local failure rate will be assessed at the time point of 24 months.
|
The time from diagnostic biopsy to documented progression of intrathoracic disease as assessed by CT or X-ray imaging. |
The local failure rate will be assessed at the time point of 24 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival
Prazo: Median time to PFS in study population. Expected to be within 24 months.
|
Time from diagnostic biopsy to first documented clinical or radiographic evidence of local progression or new metastatic disease. |
Median time to PFS in study population. Expected to be within 24 months.
|
|
Overall survival
Prazo: Median time to OS in study population. Expected to be within 24 months.
|
Time from diagnostic biopsy to death of the patient. |
Median time to OS in study population. Expected to be within 24 months.
|
|
Acute radiation toxicity
Prazo: Expected to be within 3 months.
|
Toxicity during and in the 3 months after radiotherapy as defined by CTCAE v.5 for esophagus, skin, lung, heart, and subcutaneous tissue. |
Expected to be within 3 months.
|
|
Late radiation toxicity
Prazo: Late toxicity will be assessed up to 24 months post-treatment.
|
Toxicity seen 3 months after radiotherapy as defined by CTCAE v.5 for esophagus, skin, lung, heart, and subcutaneous tissue. |
Late toxicity will be assessed up to 24 months post-treatment.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yee Don, MD, Cross Cancer Institute, Alberta Health Services
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IIT-0015
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .